Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by FORE Biotherapeutics

FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics to Present Plixorafenib Abstract at the 2025 American Society of Clinical Oncology Annual Meeting
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics Presents New Plixorafenib Results at AACR 2025 Demonstrating Pharmacodynamic Effect in Clinical Tumor Biopsies and Decreased V600E Mutant Allele Frequency in ctDNA of 85% of Patients
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics to Present Two Plixorafenib Abstracts at the American Association for Cancer Research Annual Meeting 2025
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics to Participate in the Raymond James Private Biotech Symposium
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics Highlights Recent Pipeline Achievements for its Targeted-Oncology Program and Provides Strategic Objectives for 2025
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics to Participate in the Wells Fargo Virtual Private Biotech Symposium
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics to Participate in Upcoming November Conferences
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics to Present Nonclinical Data at the 2024 AACR Annual Meeting Supporting Superior Potency for Plixorafenib Compared with BRAF or Pan-Raf Inhibitors, When Combined with MEK Inhibition
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics to Present at the 2023 RBC Capital Markets Private Company Conference
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics Announces Oral Presentation at SNO 2023 Reporting Updated Phase 1/2a Results for Plixorafenib in BRAF V600 Advanced Solid Tumors, Including Novel Data for Patients with BRAF V600 Primary CNS Tumors
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data at the Society for Neuro-Oncology 2023 Annual Meeting
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics to Present Plixorafenib Nonclinical Data Highlighting Potential Differentiation at the 2023 AACR-NCI-EORTC International Conference
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics to Present Promising New Data from Phase 1/2a Trial Evaluating Plixorafenib (FORE8394) in Patients With BRAF-Altered Advanced Solid and Central Nervous System Tumors at ASCO 2023
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From FORE Biotherapeutics
Via Business Wire
FORE Biotherapeutics Receives FDA Orphan Drug Designation for FORE8394 for the Treatment of Primary Brain and CNS Malignancies
From FORE Biotherapeutics
Via Business Wire
Fore Biotherapeutics Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394 in BRAF-Mutated Solid and Brain Tumors
From Fore Biotherapeutics
Via Business Wire
Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394 for the Treatment of Cancers Harboring BRAF Class 1 and Class 2 Alterations
From Fore Biotherapeutics
Via Business Wire
Fore Biotherapeutics Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394 in Patients With Advanced Tumors With Activating BRAF Alterations at ESMO 2022
From Fore Biotherapeutics
Via Business Wire
Fore Biotherapeutics to Present Phase 1/2a Data on FORE8394, a Next-Generation BRAF Inhibitor, at ESMO 2022
From Fore Biotherapeutics
Via Business Wire
Fore Biotherapeutics Appoints Matthew E. Ros as Chief Executive Officer
From Fore Biotherapeutics
Via Business Wire
Fore Biotherapeutics Issues Statement
From Fore Biotherapeutics
Via Business Wire
Fore Biotherapeutics Continues to Build Leadership Team with Executive and Board Appointments
From Fore Biotherapeutics
Via Business Wire
Fore Biotherapeutics Strengthens Leadership Team with Executive and Board Appointments
From Fore Biotherapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS